Open Access
Pharmacological advances in mitochondrial therapy
Publication type: Journal Article
Publication date: 2021-03-01
scimago Q1
wos Q1
SJR: 3.591
CiteScore: 17.1
Impact factor: 10.8
ISSN: 23523964
PubMed ID:
33647769
General Biochemistry, Genetics and Molecular Biology
General Medicine
Abstract
Mitochondria play a vital role in cellular metabolism and are central mediator of intracellular signalling, cell differentiation, morphogenesis and demise. An increasingly higher number of pathologies is linked with mitochondrial dysfunction, which can arise from either genetic defects affecting core mitochondrial components or malfunctioning pathways impairing mitochondrial homeostasis. As such, mitochondria are considered an important target in several pathologies spanning from neoplastic to neurodegenerative diseases as well as metabolic syndromes. In this review we provide an overview of the state-of-the-art in mitochondrial pharmacology, focusing on the novel compounds that have been generated in the bid to correct mitochondrial aberrations. Our work aims to serve the scientific community working on translational medical science by highlighting the most promising pharmacological approaches to target mitochondrial dysfunction in disease.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
|
|
|
International Journal of Molecular Sciences
4 publications, 4.49%
|
|
|
Nature Communications
3 publications, 3.37%
|
|
|
Molecules
2 publications, 2.25%
|
|
|
Metabolites
2 publications, 2.25%
|
|
|
Cells
2 publications, 2.25%
|
|
|
Molecular Metabolism
2 publications, 2.25%
|
|
|
Antioxidants
2 publications, 2.25%
|
|
|
Cell Death and Disease
2 publications, 2.25%
|
|
|
Journal of the American Society of Nephrology : JASN
2 publications, 2.25%
|
|
|
NeoReviews
1 publication, 1.12%
|
|
|
Biomedicines
1 publication, 1.12%
|
|
|
Biology
1 publication, 1.12%
|
|
|
Frontiers in Molecular Neuroscience
1 publication, 1.12%
|
|
|
Cell Biology and Toxicology
1 publication, 1.12%
|
|
|
Nature Reviews Cardiology
1 publication, 1.12%
|
|
|
Current environmental health reports
1 publication, 1.12%
|
|
|
Saudi Pharmaceutical Journal
1 publication, 1.12%
|
|
|
Molecular Therapy - Nucleic Acids
1 publication, 1.12%
|
|
|
Biochimica et Biophysica Acta - General Subjects
1 publication, 1.12%
|
|
|
Molecular Neurobiology
1 publication, 1.12%
|
|
|
Cellular and Molecular Immunology
1 publication, 1.12%
|
|
|
Journal of Agricultural and Food Chemistry
1 publication, 1.12%
|
|
|
Neurotoxicity Research
1 publication, 1.12%
|
|
|
British Journal of Pharmacology
1 publication, 1.12%
|
|
|
Neuroscientist
1 publication, 1.12%
|
|
|
Frontiers in Aging Neuroscience
1 publication, 1.12%
|
|
|
Stem Cells
1 publication, 1.12%
|
|
|
Journal of Clinical Pathology
1 publication, 1.12%
|
|
|
Advances in Experimental Medicine and Biology
1 publication, 1.12%
|
|
|
1
2
3
4
|
Publishers
|
2
4
6
8
10
12
14
16
|
|
|
Springer Nature
16 publications, 17.98%
|
|
|
MDPI
15 publications, 16.85%
|
|
|
Elsevier
12 publications, 13.48%
|
|
|
Wiley
7 publications, 7.87%
|
|
|
Frontiers Media S.A.
6 publications, 6.74%
|
|
|
Bentham Science Publishers Ltd.
4 publications, 4.49%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
4 publications, 4.49%
|
|
|
Cold Spring Harbor Laboratory
3 publications, 3.37%
|
|
|
American Chemical Society (ACS)
2 publications, 2.25%
|
|
|
SAGE
2 publications, 2.25%
|
|
|
BMJ
2 publications, 2.25%
|
|
|
IMR Press
2 publications, 2.25%
|
|
|
American Academy of Pediatrics
1 publication, 1.12%
|
|
|
King Saud University
1 publication, 1.12%
|
|
|
Oxford University Press
1 publication, 1.12%
|
|
|
American Society for Clinical Investigation
1 publication, 1.12%
|
|
|
Pharmaceutical Society of Korea
1 publication, 1.12%
|
|
|
American Physiological Society
1 publication, 1.12%
|
|
|
Federation of American Societies for Experimental Biology (FASEB)
1 publication, 1.12%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 1.12%
|
|
|
Taylor & Francis
1 publication, 1.12%
|
|
|
A and V Publications
1 publication, 1.12%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 1.12%
|
|
|
2
4
6
8
10
12
14
16
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
89
Total citations:
89
Citations from 2024:
45
(50.56%)
Cite this
GOST |
RIS |
BibTex
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.ebiom.2021.103244
UR - https://doi.org/10.1016/j.ebiom.2021.103244
TI - Pharmacological advances in mitochondrial therapy
T2 - EBioMedicine
AU - Singh, Aarti
AU - Faccenda, D.
AU - Campanella, Michelangelo
PY - 2021
DA - 2021/03/01
PB - Elsevier
SP - 103244
VL - 65
PMID - 33647769
SN - 2352-3964
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2021_Singh,
author = {Aarti Singh and D. Faccenda and Michelangelo Campanella},
title = {Pharmacological advances in mitochondrial therapy},
journal = {EBioMedicine},
year = {2021},
volume = {65},
publisher = {Elsevier},
month = {mar},
url = {https://doi.org/10.1016/j.ebiom.2021.103244},
pages = {103244},
doi = {10.1016/j.ebiom.2021.103244}
}